Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion

BACKGROUND: Patients with HER2-overexpressing metastatic breast cancer, despite initially benefiting from the monoclonal antibody trastuzumab and the EGFR/HER2 tyrosine kinase inhibitor lapatinib, will eventually have progressive disease. HER2-based vaccines induce polyclonal antibody responses agai...

詳細記述

保存先:
書誌詳細
主要な著者: Hamilton, Erika, Blackwell, Kimberly, Hobeika, Amy C, Clay, Timothy M, Broadwater, Gloria, Ren, Xiu-Rong, Chen, Wei, Castro, Henry, Lehmann, Frederic, Spector, Neil, Wei, Junping, Osada, Takuya, Lyerly, H Kim
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2012
主題:
Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3306270/
https://ncbi.nlm.nih.gov/pubmed/22325452
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-10-28
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料